Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05966753 · ClinicalTrials.gov registry record
Describing Patient With DME, Their Patient Journey and Disease Progression
A clinical trial of Diabetic Macular Edema, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 221,004
- Enrollment target
- 1
- Study location
NCT05966753 is a study of Diabetic Macular Edema that has completed, run by Boehringer Ingelheim. The registered enrollment target is 221,004 participants, above the 286-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (77174% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05966753, a study of Diabetic Macular Edema, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 221,004 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to characterize patients with diabetic macular edema (DME), their progression, the treatment received and associate the functional and physiological outcomes related to the treatment.
Conditions Studied
Study Locations (1)
Massachusetts
- CorEvitas HQ - Waltham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 221,004 participants |
| Start Date | 2023-08-03 |
| Est. Completion | 2023-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05966753
The ClinicalTrials.gov registry entry for NCT05966753 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 221,004 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 286-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (77174% higher). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Macular Edema appearing as the primary indexed condition, and to 0 interventions.
NCT05966753 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05966753 about?
NCT05966753 is a clinical study titled "Describing Patient With DME, Their Patient Journey and Disease Progression". This study aims to characterize patients with diabetic macular edema (DME), their progression, the treatment received and associate the functional and physiological outcomes related to the treatment.
What is the current status of trial NCT05966753?
This trial is currently completed. The enrollment target is 221,004 participants. The study started on 2023-08-03. Estimated completion is 2023-12-31.
What conditions does trial NCT05966753 study?
This clinical trial studies the following conditions: Diabetic Macular Edema.
Who is sponsoring clinical trial NCT05966753?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05966753 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
RECRUITING · Phase 1
-
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
RECRUITING · Phase 3
-
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.